Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.2.0.727
Commitments and Contingencies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended 30 Months Ended
Dec. 24, 2013
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Jun. 30, 2015
Cost of clinical trial lab   $ 150,107 $ 93,581 $ 500,708 $ 173,233   $ 1,202,536
Aggregate principal cash obligation and commitments amount   1,358,888   1,358,888     1,358,888
Principal cash obligations and commitments included in current liabilities   112,907   112,907     $ 112,907
Dr Kathleen P Mullinix [Member]              
Annual cash compensation   6,250 6,250 12,500 12,500 $ 25,000  
Theradex Systems, Inc [Member]              
Clinical costs charged to operations   150,107 93,581 500,708 173,233    
Theradex Systems, Inc [Member] | Phase 1 Clinical [Member]              
Estimated total clinical costs to be charged to operations       $ 2,615,000      
Percentage of clinical trial service       60.00%      
Percentage of clinical center laboratory cost       40.00%      
NDA Consulting Corp [Member]              
Consulting and advisory fees $ 4,000 $ 4,000 $ 4,000 $ 8,000 $ 8,000